30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC
| Autor: | Lopez, P. Garrido 1, Girard, N. 2, Cho, B.C. 3, Sabari, J. 4, Spira, A. 5, Sanborn, R.E. 6, Goto, K. 7, Yang, J.C-H. 8, Curtin, J. 9, Lyu, X. 10, He, A. 11, Penton, J. 12, Edwards, J. 12, Massin, G. Low 13, Xia, K. 9, Chioda, M. 9, Thayu, M. 9, Knoblauch, R.E. 9, Mahadevia, P. 9, Leighl, N. 14 |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology April 2023 18(4) Supplement:S36-S37 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|